Evolent Health Inc (NYSE:EVH) – Research analysts at Svb Leerink boosted their Q4 2019 earnings per share estimates for shares of Evolent Health in a report released on Friday, March 29th, according to Zacks Investment Research. Svb Leerink analyst D. Larsen now expects that the technology company will earn $0.06 per share for the quarter, up from their previous forecast of $0.05.
Separately, Zacks Investment Research upgraded Evolent Health from a “sell” rating to a “hold” rating in a research report on Friday, April 19th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Evolent Health has an average rating of “Buy” and a consensus price target of $26.54.
Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Tuesday, February 26th. The technology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Evolent Health had a negative return on equity of 2.39% and a negative net margin of 8.40%. The business had revenue of $193.10 million for the quarter, compared to the consensus estimate of $188.66 million. During the same quarter in the prior year, the company earned ($0.04) earnings per share. Evolent Health’s quarterly revenue was up 69.8% compared to the same quarter last year.
Institutional investors and hedge funds have recently modified their holdings of the business. Parkside Financial Bank & Trust increased its holdings in Evolent Health by 57.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,628 shares of the technology company’s stock worth $72,000 after purchasing an additional 1,327 shares in the last quarter. We Are One Seven LLC acquired a new stake in shares of Evolent Health in the fourth quarter valued at about $99,000. Virtu Financial LLC acquired a new stake in shares of Evolent Health in the first quarter valued at about $143,000. DekaBank Deutsche Girozentrale increased its stake in shares of Evolent Health by 235.4% in the third quarter. DekaBank Deutsche Girozentrale now owns 6,205 shares of the technology company’s stock valued at $156,000 after buying an additional 4,355 shares during the period. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in shares of Evolent Health in the first quarter valued at about $162,000.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Story: What is a Leveraged Buyout (LBO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.